delcath.com (DCTH) - Company Sales Volume

Corporate emblem and logo of delcath.com (DCTH)

Delcath Systems, Inc. (DCTH) management is focused on bringing liver cancer therapy systems to market, successfully overcoming regulatory barriers. The company's sales volatility clearly confirms this trajectory, where 0.11 represents the latest metric reading. The transparency of technology implementation in clinics allows management to effectively scale distribution, which significantly increases overall business margins as the volume of orders for consumables grows.

DCTH Delcath Corp: Company Revenue in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Delcath Systems (DCTH)

- market price and analyst price targets:
General company analysis:Delcath Corp, DCTH
Signature product of Delcath Systems

Delcath Systems, Inc. (DCTH) is developing innovative therapies within the high-tech biotechnology sector. By analyzing the company's current execution metrics, investors are assessing the volume of actually recognized revenue from product commercialization. This metric measures the issuer's ability to generate cash flow without owning its own plants, leveraging production outsourcing. Steady sales growth confirms market demand for these developments, ensuring the stability of the shares within institutional fund portfolios.

Key competitors

Company Total Revenue BeiGene Oncology ONC|Revenue and Sales Volume HALO|revmed.com - Company Sales Volume|Revenue and Sales Volume AAPG (Ascentage Pharma)|CG Oncology Inc (CGON) - Company Total Revenue|URGN - Company Revenue|BCAX: Company Revenue|PSNL: Revenue and Sales Volume|Company Sales erasca.com|YMAB (Y-mAbs Therapeutics, Inc.) - Revenue and Sales Volume|Revenue and Sales Volume Aura Biosciences Inc|Company Sales CADL (Candel Therapeutics)|Company Total Sales ARAY|Revenue and Sales Volume SLS (SELLAS Life Sciences Group)|Company Sales Revenue ACTU|CTOR: Company Sales|Company Sales Revenue HURA (TuHURA Biosciences, Inc.)|Protara (TARA) - Company Revenue|FATE - Company Gross Revenue|Company Sales WHWK|Company Total Revenue TScan TCRX|Company Revenue Champions Oncology (CSBR)|Company Gross Revenue xbiotech.com|CEL-SCI - Company Sales|Company Total Sales OSTX (OS Therapies, Inc.)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics, Inc.|adlainortye.com (ANL) - Company Revenue|Company Sales Veru Inc|Company Revenue Tempest Tx|Xilio (XLO) - Company Gross Revenue|Company Sales RENB (Renovaro Inc.)|MURA (muraloncology.com) - Company Sales Revenue|Revenue and Sales Volume KAPA (Kairos Pharma)|Company Gross Revenue OnKure Therapeutics, Inc. (OKUR)|GDTC - Company Revenue|CRIS (Curis, Inc.) - Company Sales Volume|APLM: Revenue and Sales Volume|Company Sales tharimmune.com|Company Sales ADVB|Genprex Inc. (GNPX) - Company Gross Revenue|Revenue and Sales Volume CLDI|Sunshine Biopharma Inc. - Company Sales Volume|Revenue and Sales Volume XBIO (Xenetic Biosciences, Inc.)|SLRX - Company Sales|PPBT: Company Sales|American Oncology Network - Company Total Sales|BGNE: Revenue and Sales Volume|Checkpoint Therapeutics Inc - Company Sales Revenue|ELEV (Elevation Oncology, Inc.) - Revenue and Sales Volume|Company Sales iCAD Corp (ICAD)|Revenue and Sales Volume IKNA|Revenue and Sales Volume Notable Labs Ltd (NTBL)|Company Revenue Viracta Therapeutics, Inc. VIRX|MOR: Company Sales Volume|NAYA Biosciences - Revenue and Sales Volume|ascentage.com (AAPGV) - Company Sales